Prospectus Supplement
(To Prospectus Dated February 10, 2020)
$500,000,000 1.900% Senior Notes due 2025
$750,000,000 2.200% Senior Notes due 2027
$1,250,000,000 2.450% Senior Notes due 2030
$1,250,000,000 3.150% Senior Notes due 2040
$1,250,000,000 3.375% Senior Notes due 2050
We are offering
$500,000,000 aggregate principal amount of 1.900% Senior Notes due 2025 (the 2025 notes), $750,000,000 aggregate principal amount of 2.200% Senior Notes due 2027 (the 2027 notes), $1,250,000,000 aggregate
principal amount of 2.450% Senior Notes due 2030 (the 2030 notes), $1,250,000,000 aggregate principal amount of 3.150% Senior Notes due 2040 (the 2040 notes) and $1,250,000,000 aggregate principal amount
of 3.375% Senior Notes due 2050 (the 2050 notes and, together with the 2025 notes, the 2027 notes, the 2030 notes and the 2040 notes, the notes).
Interest on the notes will be payable in cash semi-annually in arrears on February 21 and August 21 of each year, beginning August 21,
2020.
The notes will be our senior unsecured obligations and will rank equally with all of our other existing and future senior unsecured
indebtedness. We may redeem each series of the notes, at any time in whole or from time to time in part, at the redemption prices described in this prospectus supplement.
Investing in the notes involves risks that are described in the Risk Factors section of this
prospectus supplement beginning on page S-6.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per
2025
Note
|
|
|
Total
|
|
|
Per
2027
Note
|
|
|
Total
|
|
|
Per
2030
Note
|
|
|
Total
|
|
|
Per
2040
Note
|
|
|
Total
|
|
|
Per
2050
Note
|
|
|
Total
|
|
Public Offering Price
|
|
|
99.796%
|
|
|
$
|
498,980,000
|
|
|
|
99.787
|
%
|
|
$
|
748,402,500
|
|
|
|
99.965
|
%
|
|
$
|
1,249,562,500
|
|
|
|
99.603
|
%
|
|
$
|
1,245,037,500
|
|
|
|
99.962
|
%
|
|
$
|
1,249,525,000
|
|
Underwriting Discount
|
|
|
0.350%
|
|
|
$
|
1,750,000
|
|
|
|
0.400
|
%
|
|
$
|
3,000,000
|
|
|
|
0.450
|
%
|
|
$
|
5,625,000
|
|
|
|
0.750
|
%
|
|
$
|
9,375,000
|
|
|
|
0.875
|
%
|
|
$
|
10,937,500
|
|
Proceeds, before expenses, to Amgen
|
|
|
99.446%
|
|
|
$
|
497,230,000
|
|
|
|
99.387
|
%
|
|
$
|
745,402,500
|
|
|
|
99.515
|
%
|
|
$
|
1,243,937,500
|
|
|
|
98.853
|
%
|
|
$
|
1,235,662,500
|
|
|
|
99.087
|
%
|
|
$
|
1,238,587,500
|
|
(1)
|
Plus accrued interest, if any, from February 21, 2020, if settlement occurs after that date.
|
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities or determined that this prospectus supplement or the accompanying prospectus is accurate or complete. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository Trust Company for the accounts of
its participants, including Clearstream Banking, société anonyme, and Euroclear Bank, S.A./N.V., as operator for the Euroclear System, against payment in New York, New York on or about February 21, 2020.
Joint Book-Running Managers
|
|
|
|
|
|
|
Citigroup
|
|
Goldman Sachs & Co. LLC
|
|
Barclays
|
|
Morgan Stanley
|
|
|
|
|
BofA Securities
|
|
J.P. Morgan
|
|
HSBC
|
|
Mizuho Securities
|
Co-Managers
|
|
|
|
|
|
|
BNP PARIBAS
|
|
Credit Suisse
|
|
Deutsche Bank Securities
|
|
MUFG
|
|
|
|
|
RBC Capital Markets
|
|
SMBC Nikko
|
|
Wells Fargo Securities
|
|
Ramirez & Co., Inc.
|
The date of this prospectus supplement is February 18, 2020.